Home
    Disclaimer
    MDEA molecular structure

    MDEA Stats & Data

    Mde Eve
    NPS DataHub
    MW243.73
    FormulaC12H18ClNO2
    CAS74341-78-9
    IUPAC1-(1,3-benzodioxol-5-yl)-N-ethylpropan-2-amine hydrochloride
    SMILES[Cl-].CCNC(C)Cc1ccc2OCOc2c1.[H+]
    InChIKeyIBDIPBWIXJRJQM-UHFFFAOYSA-N
    Phenethylamines; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen
    Chemical Class Amphetamine
    Psychoactive Class Psychedelic / Stimulant

    Pharmacology

    DrugBank
    State Solid

    Description

    3,4-Methylenedioxyamphetamine (also known as MDA, and Tenamfetamine, or colloquially as "Sally", "Sass", or "Sass-a-frass") is a synthetic entactogen of the amphetamine chemical class. It produces long-lived entactogenic, stimulant and mild psychedelic effects that include stimulation, anxiety suppression, enhanced feelings of empathy, affection, and sociability, and euphoria when administered. MDA was first synthesized in 1910 but its psychoactive effects were not discovered until in 1930. It was used in animal and human trials between 1939 and 1941 and from 1949 to 1957. More than 500 human subjects were given MDA in an investigation of its potential use as either an antidepressant or anorectic. By 1958, it was successfully patented as a cough suppressant and ataractic. By 1961 it was patented as an anorectic under the trade name "Amphedoxamine".citation needed Contemporary reports suggest that MDA emerged as a recreational drug towards the end of 1967, meaning its use predates its more widely used relative MDMA (Ecstasy). As with MDMA, MDA is thought to act primarily as a serotonin-norepinephrine-dopamine reuptake inhibitor and releasing agent.citation needed However, MDA is significantly more potent by weight and subjective intensity relative to MDMA.

    Receptor Profile

    Receptor Actions

    Inhibitors
    Serotonin-dopamine-norepinephrine reuptake inhibitor (SNDRI)
    Other
    Serotonin-dopamine-norepinephrine releasing agent (SNDRA)

    Effect Profile

    Curated + 9 Reports
    Psychedelic 0.8

    Moderate body load with low headspace

    Visual Intensity×3
    0
    Headspace Depth×3
    1
    Auditory Effects×1
    0
    Body Load / Somatic Effects×1
    7
    Empathogen 6.1

    Strong euphoria and sensory enhancement with moderate stimulation, low empathy

    Empathy / Social Openness×3
    3
    Euphoria / Mood Elevation×2
    10
    Stimulation×1
    6
    Sensory Enhancement×1
    8
    Stimulant 4.8

    Strong euphoria and anxiety/jitters with mild stimulation, low focus

    Stimulation / Energy×3
    4
    Euphoria / Mood Lift×2
    10
    Focus / Productivity×2
    3
    Anxiety / Jitters×1
    10

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1d Half tolerance 12d Baseline ~21d

    Experience Report Analysis

    Erowid
    9 Reports
    2000–2012 Date Range
    2 With Age Data
    19 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 9 experience reports (9 Erowid)

    9 Reports
    19 Effects Detected
    8 Positive
    8 Adverse
    3 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 8

    Focus Enhancement 66.7% 70%
    Stimulation 66.7% 70%
    Color Enhancement 55.6% 70%
    Empathy 55.6% 70%
    Euphoria 55.6% 70%
    Tactile Enhancement 55.6% 70%
    Body High 33.3% 70%
    Introspection 33.3% 70%

    Adverse Effects 8

    Confusion 55.6% 70%
    Jaw Clenching 55.6% 70%
    Increased Heart Rate 44.4% 70%
    Anxiety 44.4% 70%
    Sweating 44.4% 70%
    Nausea 44.4% 70%
    Headache 33.3% 70%
    Muscle Tension 33.3% 70%

    Real-World Dose Distribution

    62K Doses

    From 12 individual dose entries

    Oral (n=7)

    Median: 100.0mg 25th: 100.0mg 75th: 137.5mg 90th: 150.0mg
    mg/kg median: 1.378 mg/kg 75th: 1.488

    Form / Preparation

    Most common forms and preparations reported

    Legal Status

    Controlled internationally under the UN Convention on Psychotropic Substances 1971.
    Country Status Notes
    Austria MDEA is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).
    Brazil MDEA is illegal to possess, produce or sell as it is listed on Portaria SVS/MS nº 344 as "MDE".
    Canada MDEA is listed on the CSDA in Schedule I.
    France MDEA is scheduled as a "stupéfiant", i.e. a recognized drug of abuse. It is illegal to possess, buy, sell or manufacture.
    Germany MDEA is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of April 15, 1991. It is illegal to manufacture, possess, import, export, buy, sell, procure or to dispense it without a license. ( MDE )
    Switzerland MDEA is a controlled substance specifically named under Verzeichnis D.
    United Kingdom MDEA is a Class A drug.
    United States In the United States, MDEA was introduced recreationally in 1985 as a legal substitute to the newly banned MDMA. MDEA was made a Schedule 1 substance in the United States on October 15, 1987.
    ← Back to MDEA